Developer docs
API playgroundTry for free, no card

Search company profiles

Anemocyte

Full company profile

uuid000hboq

Namestring
Anemocyte
Legal namestring
Anemocyte S.r.l.
Websiteurl
anemocyte.com
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Anemocyte S.r.l. is an Italian Biotech Manufacturing Organization (BMO) headquartered in Gerenzano, Italy, specializing in plasmid DNA (pDNA) and mRNA development and manufacturing for advanced therapy applications. The company produces nucleic acid starting materials across three quality grades (R&D under ISO 9001:2015, High Quality, and full GMP for EMA/FDA-regulated clinical and commercial use), with batch sizes ranging from 1mg to multigram scale. Its core technology platform includes the proprietary AMCAP™ mRNA capping technology and the AMClarity visual inspection division, which supplies defective reference sets and GMP qualification services to pharmaceutical and biotech clients. Manufacturing capacity comprises 500 sqm of dedicated production and QC space plus 800 sqm of cleanrooms added in a 2019 expansion.

Anemocyte serves cell and gene therapy developers, mRNA vaccine and therapy developers, viral vector manufacturers, and pharmaceutical CDMOs requiring process development support. Named customers include Genenta Science (pDNA and cell banks for Temferon™ immunotherapy in glioblastoma and renal cell carcinoma) and Altheia Science (Master Cell Banks and pDNA for autoimmune disease cell and gene therapy programs). The company generates revenue through quote-based, multi-year contract manufacturing agreements, supplemented by an e-commerce storefront at shop.anemocyte.com for off-the-shelf mRNA, pDNA, and IVT kits targeting smaller research customers.

The business is family-owned, debt-free, and structured as a Single Shareholder Private Limited-Liability Company (S.r.l.) under Italian law with €530,000 of fully paid share capital. In March 2025, Anemocyte opened Anemocyte Inc., a wholly-owned US subsidiary in Miami, Florida, appointing an Account Director to develop North American business. Distribution relies on direct enterprise sales, industry conference participation (ISCT, ASGCT, CPHI, BIO, TIDES, Advanced Therapies Week), and national pavilions at international events, with geographic coverage spanning Italy, Switzerland, Germany, Spain, Portugal, the United States, and Japan.

Short descriptiontext

Anemocyte is an Italian Biotech Manufacturing Organization specializing in plasmid DNA and mRNA development and manufacturing for cell and gene therapy, vaccine, and viral vector clients across R&D to GMP grades.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersGerenzago, Italy
HQ citystring
Gerenzago
HQ countrystring
Italy
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
plasmid DNA manufacturing, mRNA contract manufacturing, cell and gene therapy CDMO, GMP plasmid production, nucleic acid manufacturing
Industry3 codes
PRIMARYHLAGABAE
Gene Therapy (Viral Vector/Plasmid) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAF
mRNA/LNP & Nucleic Acid Therapeutics CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAAACAJ
Gene Therapy Vector Manufacturing & CDMO Services
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical and Medicine Manufacturing3254
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Biotech Contract Manufacturing Services
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1Contract Manufacturing Services (pDNA)
TypeOne Time License
Description

Plasmid DNA manufacturing services at R&D, High Quality, and GMP grade levels for viral vector production, cell therapies, gene therapies, and vaccine development. Pricing based on batch size (1mg to multigram) and quality grade requirements.

anemocyte.com
2Contract Manufacturing Services (mRNA)
TypeOne Time License
Description

mRNA development and manufacturing services including template design, IVT, capping, purification, and formulation for therapeutic applications

anemocyte.com
3AMClarity Inspection Services
TypeProfessional Services
Description

Visual inspection qualification services including custom defective reference sets and GMP consulting/training for pharmaceutical and biotech companies

anemocyte.com
4Related Services
TypeProfessional Services
Description

Process development, cryopreservation, stability studies, and secondary packaging services supporting the core manufacturing offerings

anemocyte.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Supply Chain
Pricing details3 tiers
1R&D Grade pDNA - ISO 9001:2015 compliant for early-stage research
ModelUnit PricingBilling cadenceMulti-year contract
Notes

Suitable for preclinical research; production focuses on speed and cost-efficiency

anemocyte.com
2High-Quality (HQ) Grade pDNA - GMP guidelines with full traceability
ModelUnit PricingBilling cadenceMulti-year contract
Notes

For toxicology studies and early clinical stages; includes comprehensive documentation, Certificates of Analysis, and TSE/BSE statements

anemocyte.com
3GMP Grade pDNA - Strict regulatory standards for clinical/commercial
ModelUnit PricingBilling cadenceMulti-year contract
Notes

For advanced clinical and commercial applications; full regulatory filing documentation with batch-specific audits

anemocyte.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 3 records shown
1AMCAP™
Description

mRNA capping technology platform - a smarter way to cap mRNA

anemocyte.com
+2 more records
Core offering1 text field

Anemocyte is a Biotech Manufacturing Organization (BMO) that develops and manufactures plasmid DNA (pDNA) and mRNA at R&D, High Quality, and GMP grades for biotech and pharmaceutical companies developing advanced therapies. The company delivers end-to-end services from process development and DNA template design through IVT, capping, purification, fill/finish, and cryopreservation, with proprietary AMCAP™ mRNA capping technology and AMClarity visual inspection solutions. Its customer base includes cell and gene therapy developers, mRNA vaccine developers, and viral vector manufacturers requiring reliable supply of nucleic acid starting materials.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Facility expansion completed August 2019
+2 more records
Product overview1 text field

Anemocyte is a Biotech Manufacturing Organization (BMO) offering a portfolio of nucleic acid manufacturing solutions centered on two core technology platforms: Plasmid DNA (pDNA) and mRNA development and manufacturing. The portfolio includes the proprietary AMCAP™ capping technology and the AMClarity visual inspection division. Anemocyte provides end-to-end services from R&D to GMP manufacturing, with supporting services including cryopreservation, stability studies, secondary packaging, and process development. The company positions itself as the world's first BMO, offering flexible manufacturing capabilities across multiple quality grades (R&D, HQ, GMP) for plasmid DNA and mRNA products.

Product and service8 records
1Plasmid DNA (pDNA) Development and Manufacturing
CategoryContract Manufacturing Services
Description

Contract manufacturing of plasmid DNA in three quality grades (R&D, High Quality, and GMP) for biotech and pharmaceutical companies developing viral vectors, cell therapies, gene therapies, and vaccines. Batch sizes range from 1mg to multigram with full regulatory documentation and Certificates of Analysis.

2mRNA Development and Manufacturing
CategoryContract Manufacturing Services
Description

Contract manufacturing of mRNA for vaccines and advanced therapies, covering the full production workflow from DNA template design through in vitro transcription (IVT), capping, purification using membrane chromatography and monolithic columns, and final drug substance formulation.

3AMCAP™
CategoryProprietary Technology Platform
Description

Proprietary mRNA capping technology platform providing an approach to mRNA capping for enhanced stability and efficiency, integrated within Anemocyte's mRNA manufacturing offering for vaccine and therapeutic developers.

4AMClarity
CategoryQuality Services and Products
Description

Specialized division providing precision-engineered defective reference standards and GMP qualification/training services for pharmaceutical and biotech companies' visual inspection processes.

5Cryopreservation and Storage Services
CategoryRelated Services
Description

Controlled storage and cryopreservation services with temperature options ranging from -80°C to ambient, including nitrogen cryopreservation, fully monitored with controlled access for cell banks, plasmid DNA, mRNA, and other biological materials.

6Stability Studies
CategoryRelated Services
Description

Customized stability studies tailored to client timelines and testing requirements, utilizing a panel of quality control assays for plasmid DNA, mRNA, and related biological products.

7Secondary Packaging
CategoryRelated Services
Description

Secondary packaging service providing anti-tampering boxes with sponge material protecting primary packages during shipping and preventing product shifting during delivery.

8Process Development Services
CategoryRelated Services
Description

Process optimization and development support across different production phases of plasmid DNA and mRNA manufacturing, including tech transfer activities between development and manufacturing stages.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-24
Description

Expanded strategic partnership to advance off-the-shelf LVV (Lentiviral Vector) Plasmid DNA technology platform. The partnership leverages Genenta's proprietary LVV Plasmid DNA platform to enhance Anemocyte's product offerings for advanced therapy programs across the industry.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-05-21
Description

Strategic collaboration providing Master Cell Banks and plasmid DNA for viral vector manufacturing to support Altheia's cell and gene therapy pipeline for autoimmune diseases. The partnership emphasizes speed and precision in manufacturing with Anemocyte serving as a key strategic partner accelerating path toward clinical trials.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-05-07
Description

Strategic collaboration encompassing manufacturing of critical starting materials including Cell Banks and Plasmids for viral vector production. The partnership supports Genenta's Temferon™ immunotherapy platform for Glioblastoma Multiforme and Renal Cell Carcinoma. Anemocyte provides high-quality pDNA that met Genenta's expectations for production of high-quality therapeutic products.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Aldevron is a leading CDMO specializing in plasmid DNA, mRNA, and protein manufacturing for cell and gene therapy developers — Anemocyte's core capability set, with overlapping R&D-to-GMP grade offerings and a similar advanced-therapy customer base.

2Cobra Biologics (Charles River Laboratories)
TypeDirect peer
Description

Cobra Biologics, now part of Charles River, provides plasmid DNA and viral vector manufacturing services for gene therapy and cell therapy developers — directly comparable in modality (pDNA/viral vectors) and customer profile to Anemocyte.

TypeDirect peer
Description

Vibalogics is a CDMO focused on viral vector manufacturing for gene therapies, supplying process development, GMP manufacturing, and analytical services — a closely matched peer serving overlapping advanced-therapy customers from European operations.

TypeDirect peer
Description

Celonic is a European CDMO offering GMP manufacturing for biologics, cell and gene therapies, and viral vectors — competing with Anemocyte for advanced-therapy customers seeking GMP-grade nucleic acid and viral vector production.

TypeEmerging player
Description

Polyplus, now part of Sartorius, provides plasmid DNA, transfection reagents, and process services for gene therapy and vaccine manufacturing — closely comparable upstream-pDNA capability with overlapping customer applications.

TypeEmerging player
Description

Quantoom Biosciences is an mRNA CDMO offering end-to-end mRNA production and process development for vaccines and therapeutics — overlapping with Anemocyte's mRNA manufacturing platform on the nucleic acid modality.

TypeBroad incumbent
Description

Lonza is a global CDMO leader with cell and gene therapy manufacturing services including viral vectors and mRNA — a much larger, multi-site incumbent whose pDNA/mRNA offerings compete with Anemocyte for advanced-therapy programs at higher scale.

TypeBroad incumbent
Description

Catalent is a broad CDMO with biologics, cell therapy, and plasmid DNA capabilities — a global incumbent that competes with Anemocyte for nucleic acid manufacturing programs across clinical and commercial stages.

TypeBroad incumbent
Description

Thermo Fisher's pharma services division offers plasmid DNA, viral vector, and mRNA CDMO capabilities — a large diversified incumbent with overlapping services competing for advanced-therapy customers.

TypeBroad incumbent
Description

GenScript ProBio is a CDMO offering plasmid DNA, viral vector, and cell therapy manufacturing services with global capacity — competing in Anemocyte's core nucleic acid and gene therapy modalities from an Asian and US footprint.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Anemocyte

Biotech Contract Manufacturing Servicesanemocyte.com

Anemocyte is an Italian Biotech Manufacturing Organization specializing in plasmid DNA and mRNA development and manufacturing for cell and gene therapy, vaccine, and viral vector clients across R&D to GMP grades.

What Anemocyte does

Anemocyte S.r.l. is an Italian Biotech Manufacturing Organization (BMO) headquartered in Gerenzano, Italy, specializing in plasmid DNA (pDNA) and mRNA development and manufacturing for advanced therapy applications. The company produces nucleic acid starting materials across three quality grades (R&D under ISO 9001:2015, High Quality, and full GMP for EMA/FDA-regulated clinical and commercial use), with batch sizes ranging from 1mg to multigram scale. Its core technology platform includes the proprietary AMCAP™ mRNA capping technology and the AMClarity visual inspection division, which supplies defective reference sets and GMP qualification services to pharmaceutical and biotech clients. Manufacturing capacity comprises 500 sqm of dedicated production and QC space plus 800 sqm of cleanrooms added in a 2019 expansion.

Anemocyte serves cell and gene therapy developers, mRNA vaccine and therapy developers, viral vector manufacturers, and pharmaceutical CDMOs requiring process development support. Named customers include Genenta Science (pDNA and cell banks for Temferon™ immunotherapy in glioblastoma and renal cell carcinoma) and Altheia Science (Master Cell Banks and pDNA for autoimmune disease cell and gene therapy programs). The company generates revenue through quote-based, multi-year contract manufacturing agreements, supplemented by an e-commerce storefront at shop.anemocyte.com for off-the-shelf mRNA, pDNA, and IVT kits targeting smaller research customers.

The business is family-owned, debt-free, and structured as a Single Shareholder Private Limited-Liability Company (S.r.l.) under Italian law with €530,000 of fully paid share capital. In March 2025, Anemocyte opened Anemocyte Inc., a wholly-owned US subsidiary in Miami, Florida, appointing an Account Director to develop North American business. Distribution relies on direct enterprise sales, industry conference participation (ISCT, ASGCT, CPHI, BIO, TIDES, Advanced Therapies Week), and national pavilions at international events, with geographic coverage spanning Italy, Switzerland, Germany, Spain, Portugal, the United States, and Japan.

Anemocyte firmographics

Firmographics
Name
Anemocyte
Legal name
Anemocyte S.r.l.
Website
https://anemocyte.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
11–50 employees
Short description
Anemocyte is an Italian Biotech Manufacturing Organization specializing in plasmid DNA and mRNA development and manufacturing for cell and gene therapy, vaccine, and viral vector clients across R&D to GMP grades.
Ownership category
akta.pro rank

Anemocyte industry classification

Industry
Product category
Biotech Contract Manufacturing Services
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAGABAE
Gene Therapy (Viral Vector/Plasmid) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAF
mRNA/LNP & Nucleic Acid Therapeutics CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAAACAJ
Gene Therapy Vector Manufacturing & CDMO Services
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)

Keywords

  • Plasmid DNA manufacturing
  • MRNA contract manufacturing
  • Cell and gene therapy CDMO
  • GMP plasmid production
  • Nucleic acid manufacturing

Where Anemocyte is headquartered

Location

Headquarters

HQ city
Gerenzago
HQ country
Italy
HQ region
Europe

Offices2 records

Markets served

Anemocyte business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

  1. Contract Manufacturing Services (pDNA): Plasmid DNA manufacturing services at R&D, High Quality, and GMP grade levels for viral vector production, cell therapies, gene therapies, and vaccine development. Pricing based on batch size (1mg to multigram) and quality grade requirements.
  2. Contract Manufacturing Services (mRNA): mRNA development and manufacturing services including template design, IVT, capping, purification, and formulation for therapeutic applications
  3. AMClarity Inspection Services: Visual inspection qualification services including custom defective reference sets and GMP consulting/training for pharmaceutical and biotech companies
  4. Related Services: Process development, cryopreservation, stability studies, and secondary packaging services supporting the core manufacturing offerings

Pricing tiers

ModelBillingPrice
Unit PricingMulti-year contractR&D Grade pDNA - ISO 9001:2015 compliant for early-stage research
Unit PricingMulti-year contractHigh-Quality (HQ) Grade pDNA - GMP guidelines with full traceability
Unit PricingMulti-year contractGMP Grade pDNA - Strict regulatory standards for clinical/commercial

Go-to-market motion2 records

Distribution channels4 records

Marketing channels4 records

Anemocyte product offering

Product offering

Core offering

Anemocyte is a Biotech Manufacturing Organization (BMO) that develops and manufactures plasmid DNA (pDNA) and mRNA at R&D, High Quality, and GMP grades for biotech and pharmaceutical companies developing advanced therapies. The company delivers end-to-end services from process development and DNA template design through IVT, capping, purification, fill/finish, and cryopreservation, with proprietary AMCAP™ mRNA capping technology and AMClarity visual inspection solutions. Its customer base includes cell and gene therapy developers, mRNA vaccine developers, and viral vector manufacturers requiring reliable supply of nucleic acid starting materials.

Product overview

Anemocyte is a Biotech Manufacturing Organization (BMO) offering a portfolio of nucleic acid manufacturing solutions centered on two core technology platforms: Plasmid DNA (pDNA) and mRNA development and manufacturing. The portfolio includes the proprietary AMCAP™ capping technology and the AMClarity visual inspection division. Anemocyte provides end-to-end services from R&D to GMP manufacturing, with supporting services including cryopreservation, stability studies, secondary packaging, and process development. The company positions itself as the world's first BMO, offering flexible manufacturing capabilities across multiple quality grades (R&D, HQ, GMP) for plasmid DNA and mRNA products.

Differentiator

Problem solved

Functional benefit

Brands

  • AMCAP™: mRNA capping technology platform - a smarter way to cap mRNA
  • AMClarity
  • AMClarity

Products and services

  • Plasmid DNA (pDNA) Development and Manufacturing Contract manufacturing of plasmid DNA in three quality grades (R&D, High Quality, and GMP) for biotech and pharmaceutical companies developing viral vectors, cell therapies, gene therapies, and vaccines. Batch sizes range from 1mg to multigram with full regulatory documentation and Certificates of Analysis.
  • mRNA Development and Manufacturing Contract manufacturing of mRNA for vaccines and advanced therapies, covering the full production workflow from DNA template design through in vitro transcription (IVT), capping, purification using membrane chromatography and monolithic columns, and final drug substance formulation.
  • AMCAP™ Proprietary mRNA capping technology platform providing an approach to mRNA capping for enhanced stability and efficiency, integrated within Anemocyte's mRNA manufacturing offering for vaccine and therapeutic developers.
  • AMClarity Specialized division providing precision-engineered defective reference standards and GMP qualification/training services for pharmaceutical and biotech companies' visual inspection processes.
  • Cryopreservation and Storage Services Controlled storage and cryopreservation services with temperature options ranging from -80°C to ambient, including nitrogen cryopreservation, fully monitored with controlled access for cell banks, plasmid DNA, mRNA, and other biological materials.
  • Stability Studies Customized stability studies tailored to client timelines and testing requirements, utilizing a panel of quality control assays for plasmid DNA, mRNA, and related biological products.
  • Secondary Packaging Secondary packaging service providing anti-tampering boxes with sponge material protecting primary packages during shipping and preventing product shifting during delivery.
  • Process Development Services Process optimization and development support across different production phases of plasmid DNA and mRNA manufacturing, including tech transfer activities between development and manufacturing stages.

Quantifiable outcome

  • Facility expansion completed August 2019
  • +2 more outcomes

Companies that use Anemocyte

Customer profile

Named customers2 records

Segments4 records

Ideal customer profiles2 records

Anemocyte technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Anemocyte partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • Genenta SciencecoreStrategic or Co-development Partner · 24 October 2025Expanded strategic partnership to advance off-the-shelf LVV (Lentiviral Vector) Plasmid DNA technology platform. The partnership leverages Genenta's proprietary LVV Plasmid DNA platform to enhance Anemocyte's product offerings for advanced therapy programs across the industry.
  • Altheia SciencecoreStrategic or Co-development Partner · 21 May 2025Strategic collaboration providing Master Cell Banks and plasmid DNA for viral vector manufacturing to support Altheia's cell and gene therapy pipeline for autoimmune diseases. The partnership emphasizes speed and precision in manufacturing with Anemocyte serving as a key strategic partner accelerating path toward clinical trials.
  • Genenta SciencecoreStrategic or Co-development Partner · 7 May 2025Strategic collaboration encompassing manufacturing of critical starting materials including Cell Banks and Plasmids for viral vector production. The partnership supports Genenta's Temferon™ immunotherapy platform for Glioblastoma Multiforme and Renal Cell Carcinoma. Anemocyte provides high-quality pDNA that met Genenta's expectations for production of high-quality therapeutic products.

Scale indicators7 records

Recent moves8 records

Expansion highlights6 records

Anemocyte competitors and assessment

Company assessment

Direct peers

  • Aldevron: Aldevron is a leading CDMO specializing in plasmid DNA, mRNA, and protein manufacturing for cell and gene therapy developers — Anemocyte's core capability set, with overlapping R&D-to-GMP grade offerings and a similar advanced-therapy customer base.
  • Cobra Biologics (Charles River Laboratories): Cobra Biologics, now part of Charles River, provides plasmid DNA and viral vector manufacturing services for gene therapy and cell therapy developers — directly comparable in modality (pDNA/viral vectors) and customer profile to Anemocyte.
  • Vibalogics: Vibalogics is a CDMO focused on viral vector manufacturing for gene therapies, supplying process development, GMP manufacturing, and analytical services — a closely matched peer serving overlapping advanced-therapy customers from European operations.
  • Celonic Group: Celonic is a European CDMO offering GMP manufacturing for biologics, cell and gene therapies, and viral vectors — competing with Anemocyte for advanced-therapy customers seeking GMP-grade nucleic acid and viral vector production.

Emerging players

  • Polyplus (Sartorius): Polyplus, now part of Sartorius, provides plasmid DNA, transfection reagents, and process services for gene therapy and vaccine manufacturing — closely comparable upstream-pDNA capability with overlapping customer applications.
  • Quantoom Biosciences: Quantoom Biosciences is an mRNA CDMO offering end-to-end mRNA production and process development for vaccines and therapeutics — overlapping with Anemocyte's mRNA manufacturing platform on the nucleic acid modality.

Broad incumbents

  • Lonza Group: Lonza is a global CDMO leader with cell and gene therapy manufacturing services including viral vectors and mRNA — a much larger, multi-site incumbent whose pDNA/mRNA offerings compete with Anemocyte for advanced-therapy programs at higher scale.
  • Catalent (Novo Holdings): Catalent is a broad CDMO with biologics, cell therapy, and plasmid DNA capabilities — a global incumbent that competes with Anemocyte for nucleic acid manufacturing programs across clinical and commercial stages.
  • Thermo Fisher Scientific (Patheon viral vector services): Thermo Fisher's pharma services division offers plasmid DNA, viral vector, and mRNA CDMO capabilities — a large diversified incumbent with overlapping services competing for advanced-therapy customers.
  • GenScript ProBio: GenScript ProBio is a CDMO offering plasmid DNA, viral vector, and cell therapy manufacturing services with global capacity — competing in Anemocyte's core nucleic acid and gene therapy modalities from an Asian and US footprint.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Anemocyte social profiles

Digital presence

Anemocyte compliance and trust

Trust signal

Compliance4 records

Anemocyte financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Anemocyte leadership team

Management profile

Number of profiles

Profiles1 record

Anemocyte subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Anemocyte funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Anemocyte M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Anemocyte

What does Anemocyte do?

Anemocyte is a Biotech Manufacturing Organization (BMO) that develops and manufactures plasmid DNA (pDNA) and mRNA at R&D, High Quality, and GMP grades for biotech and pharmaceutical companies developing advanced therapies. The company delivers end-to-end services from process development and DNA template design through IVT, capping, purification, fill/finish, and cryopreservation, with proprietary AMCAP™ mRNA capping technology and AMClarity visual inspection solutions. Its customer base includes cell and gene therapy developers, mRNA vaccine developers, and viral vector manufacturers requiring reliable supply of nucleic acid starting materials.

Is Anemocyte a public or private company?

Anemocyte is a private company. It is classified as family owned and is currently operating.

When was Anemocyte founded?

Anemocyte was founded in 2017. It employs 11 to 50 people.

Where is Anemocyte based?

Anemocyte is headquartered in Gerenzago, Italy, in the Europe region.

How does Anemocyte make money?

Four revenue lines are on record. Contract Manufacturing Services (pDNA) is the primary driver. The others are contract Manufacturing Services (mRNA), AMClarity Inspection Services and related Services.

Who are Anemocyte's main competitors?

Direct peers on record are Aldevron, Cobra Biologics (Charles River Laboratories), Vibalogics and Celonic Group. Emerging players are Polyplus (Sartorius) and Quantoom Biosciences. Broad incumbents are Lonza Group, Catalent (Novo Holdings), Thermo Fisher Scientific (Patheon viral vector services) and GenScript ProBio.

Does Anemocyte have an API?

No public API is recorded for Anemocyte.

What industry is Anemocyte in?

Anemocyte's product category is Biotech Contract Manufacturing Services. Its primary akta.pro industry code is HLAGABAE, Gene Therapy (Viral Vector/Plasmid) CDMO, with a secondary code of HLAGABAF, mRNA/LNP & Nucleic Acid Therapeutics CDMO. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
EIN PresswireSeven RNA leaders launch the European RNA AllianceSeven European RNA companies launched the European RNA Alliance (ERA) to provide a shared gateway to complementary RNA expertise. The non-equity alliance aims to improve access to European RNA technologies and strengthen Europe's competitiveness, with each member retaining independence.Stock TitanGenenta, Anemocyte Expand Off-the-Shelf LVV Plasmid DNA PlatformGenenta Science and Anemocyte announced a strategic partnership to expand off-the-shelf lentiviral vector plasmid DNA production. The collaboration leverages Genenta's LVV plasmid DNA technology, developed from Professor Luigi Naldini's research, to provide reliable materials from R&D to GMP grade. The partnership aims to support advanced therapy programs across the industry.GlobeNewswireGenenta and Anemocyte Announce Strategic Partnership to Advance Off-The-Shelf LVV Plasmid DNA ProductionGenenta Science and ANEMOCYTE announced a strategic collaboration to advance off-the-shelf lentiviral vector (LVV) Plasmid DNA technology, building on their existing partnership in plasmid DNA manufacturing. The technology platform, developed from foundational research by Professor Luigi Naldini, co-founder of Genenta, will enable ANEMOCYTE to provide reliable and scalable materials from R&D to GMP grade for advanced therapy programs. The collaboration marks a significant milestone for both companies in supporting the life science industry with innovative and reliable solutions.GlobeNewswireGenenta and Anemocyte announce a collaboration for the manufacturing of starting materials for cutting-edge cell-based therapiesGenenta Science and Anemocyte announced a collaboration to manufacture starting materials for cell-based therapies, including Cell Banks and Plasmids. The partnership supports Genenta's immuno-oncology trials, with Anemocyte's expertise confirmed in plasmid DNA production. The collaboration aims to advance Genenta's clinical progress.Stock TitanGenenta and Anemocyte announce a collaboration for the manufacturing of starting materials for cutting-edge cell-based therapiesGenenta and Anemocyte announced a collaboration to manufacture starting materials for cell-based therapies, including cell banks and plasmids for viral vector production. The partnership aims to advance immuno-oncology trials, with Anemocyte's expertise confirmed in producing high-quality plasmid DNA.Business Wire BlogAnemocyte Brings Italian Excellence in the Cell and Gene Therapy Sector to Phacilitate Leaders World 2020 in MiamiAnemocyte, an Italian cell and gene therapy company, will attend Phacilitate Leaders World in Miami from January 21-24, 2020. The company has tripled its plasmid production capacity since 2018 and partnered with MaxCyte for non-viral gene modification. It aims to offer innovative solutions to anticipate market demands.